Observational study of the use of 7% sodium chloride solution combined with 0,1% hyaluronic acid in therapy of adults with cystic fibrosis

A non-interventional prospective cohort study was conducted on adult patients with cystic fibrosis, who received mucolytic therapy with 7% NaCl solution combined with 0.1% hyaluronic acid (medical product Hyaneb) and 7% NaCl solution for 4 and 8 weeks. Materials and methods: A total of 24 CF patients over 18 years old were enrolled in the study. A comparative analysis of respiratory function, therapy satisfaction, efficacy and safety of treatment was conducted following 4 weeks of therapy in 7% NaCl Solution Group (n = 12) and MP Hyaneb Group (n = 12), and the dynamics of these parameters was assessed against the background of the use of MP Hyaneb for 8 weeks (n = 12). Results: At week 4 of treatment, a significantly smaller number of patients complained of nasal congestion, ears and or accumulation of mucus in the throat and chest, irritation of the throat and unpleasant taste in the MP Hyaneb Group. No significant differences in the onset and increase in the intensity of cough were achieved. No significant differences between the groups in terms of spirometry parameters were identified. Findings: MP Hyaneb showed the best tolerability compared to 7% NaCl solution in adult patients with cystic fibrosis. The use of MP Hyaneb reduces the frequency and severity of irritation of the pharyngeal mucosa, cough and nasal congestion following administration for one month.

1. Cystic fibrosis. Monograph under the editorship of Kapranova N.I., Kashirskaya N.Yu. M.: Medpraktika Publishing House, 2014, 672p. (In Russ).

2. National Consensus «Cystic fibrosis: definition, diagnostic criteria, therapy» Under the editorship of Kondratieva E.I., Kashirskaya N.Yu., Kapranova N.I., Moscow: Company BORGES LLC, 2016. (In Russ).

3. Rachinsky S.V. Commencement address. Modern problems of children’s pulmonology. M. 1970. Metrosnab Typography. 23 p. (In Russ).

4. Tarran R., Grubb B.R., Parsons D., et al. The CF salt controversy: in vivo observations and therapeutic approaches. MolCell. 2001;8:149-158.

5. Robinson M., Regnis J.A., Bailey D.L., King M., Bautovich G.J., Bye P.T. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J RespirCritCareMed. 1996;153:1503-1509.

6. Robinson M., Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52:900-903.

7. Donaldson S.H., Bennett W.D., Zeman K.L., Knowles M.R., Tarran R., and Boucher R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–250.

8. Ballmann M., von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J CystFibros. 2002;1:35-37.

9. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., Belousova E.G., Xuan W., Bye P.T.; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006; 354:229–240.

10. Smyth A.R. et al. European cystic fibrosis society standards of care: Best practice guidelines. J. Cyst. Fibros. European Cystic Fibrosis Society. 2014; 13(S1): S23–S42.

11. The Russian Federation Cystic Fibrosis Patient Registry, 2016. Under the editorship of Krasovsky S.A., Chernyak A.V., Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu., Kondratieva E.I., Gembitskaya T.E.. M.: MEDPRAKTIKA-M PH, 2018. 64 p. (In Russ).

12. ECFS patient registry. Available at: https://www.ecfs.eu/projects/ecfs-patient-registry/intro(accessed date: 19.09.2018).

13. Cantor J.O., Shteyngart B., Cerreta J.M., Liu M., Armand G., and Turino G.M. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. ProcSocExpBiol Med. 2000;225:65–71.

14. Akatsuka M., Yamamoto Y., Tobetto K., Yasui T., and Ando T. Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leucocytes. J Pharm Pharmacol. 1993;45:110–114.

15. Zahm J.M., Miliot M., Bresin A., Coraux C., and Birembaut P. The effect of hyaluronan on airway mucus transport and airway epithelial barrier integrity: potential application to the cytoprotection of airway tissue. Matrix Biol. 2011;30(7–8):389–395.

16. Buonpensiero P. et al. Hyaluronic acid improves «pleasantness» and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27(11): 870–878.

17. Ros M. et al. Hyaluronic Acid Improves the Tolerability of Hypertonic Saline in the Chronic Treatment of Cystic Fibrosis Patients: A Multicenter, Randomized, Controlled Clinical Trial. J. Aerosol Med. Pulm. Drug Deliv. 2014; 27(2): 133–137.

18. Carro L.M. et al. Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis. Med. Clin. (Barc). 2012; 138(2): 57–59.

19. Furnari M.L. et al. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: A prospective, randomized, double blind, controlled study. Ther. Adv. Respir. Dis. 2012; 6(6): 315–322.

20. Krasovsky S.A. Hyaneb to reduce intolerance to inhaled tobramycin. The 27th National Respiratory Diseases Congress, 2017. Collected papers. P. 90. (In Russ)